학술논문

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
Document Type
Article
Source
Lancet Respiratory Medicine; Oct2021, Vol. 9 Issue 10, p1111-1120, 10p
Subject
RESPIRATORY syncytial virus
BRONCHIOLITIS
HERPES zoster
CLINICAL trials
ALUMINUM hydroxide
ADULTS
VACCINES
Language
ISSN
22132600
Abstract
Copyright of Lancet Respiratory Medicine is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)